How safe and effective is DALK in the treatment of corneal scarring secondary to herpes simplex virus keratitis? The British Journal of Ophthalmology
Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.
Status: Active, not recruiting,
Condition Summary: Age-related Macular Degeneration
NEW YORK (Reuters Health) – In patients with medically uncontrolled chronic angle-closure glaucoma
without cataract, both phacoemulsification and trabeculectomy are effective but the former can have advantages,
according to Chinese researchers.
Over the past two years, I have written extensively about the human clinical trials underway for treating eye diseases using both stem cells and gene therapy. There are currently eighteen clinical trials using stem cells and sixteen trials using gene t…
The first 6 months after an open-angle glaucoma diagnosis are the most costly within the first 2 years of having the condition, report US researchers.